Related Experiment Video
Updated: Jan 31, 2026

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
Published on: October 16, 2015
Hematologists anticipate gilteritinib, a FLT3/AXL inhibitor, will be crucial for acute myeloid leukemia (AML) treatment. However, glasdegib may see limited use due to its required combination with cytarabine, an uncommon AML therapy.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Acute myeloid leukemia (AML) is a complex hematologic malignancy.
- Two novel therapies, gilteritinib and glasdegib, have received FDA approval for AML treatment.
- Understanding the clinical utility and expected integration of these new agents is crucial for treatment strategy.
More Related Videos
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
09:41Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
Published on: February 25, 2021
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Mixing Concrete
Mixing Time
Ready Mixed Concrete
Design Example: Vintage Mixing Console
The specifications for the pre-amplifier were clear. It needed to amplify the audio signal by a factor of 10, have an input impedance above 10...